UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

British journal of clinical pharmacology, 2002-11, Vol.54 (5), p.472-477

2002

Volltextzugriff (PDF)

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

Current medical research and opinion, 2008-09, Vol.24 (9), p.2575-2585

2008

Volltextzugriff (PDF)

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

Journal of clinical pharmacology, 2005-08, Vol.45 (8), p.927-934

2005

Volltextzugriff (PDF)

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Clinical pharmacology and therapeutics, 2004-05, Vol.75 (5), p.455-463

2004

Volltextzugriff (PDF)

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Clinical pharmacology and therapeutics, 2004-08, Vol.76 (2), p.167-177

2004

Volltextzugriff (PDF)

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

The American journal of cardiology, 2003, Vol.91 (1), p.33-41

2003

Volltextzugriff (PDF)

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Clinical therapeutics, 2003-02, Vol.25 (2), p.459-471

2003

Volltextzugriff (PDF)

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Clinical pharmacology and therapeutics, 2003-04, Vol.73 (4), p.322-329

2003

Volltextzugriff (PDF)

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

British journal of clinical pharmacology, 2003-01, Vol.55 (1), p.94-99

2003

Volltextzugriff (PDF)

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Current medical research and opinion, 2008-04, Vol.24 (4), p.1231-1235

2008

Volltextzugriff (PDF)

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

Coronary artery disease, 2004-03, Vol.15 (2), p.115-123

2004

Volltextzugriff (PDF)

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive

British journal of clinical pharmacology, 2004-03, Vol.57 (3), p.279-286

2004

Volltextzugriff (PDF)

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Journal of clinical pharmacology, 2002-12, Vol.42 (12), p.1352-1357

2002

Volltextzugriff (PDF)

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

The journal of clinical psychiatry, 1996-05, Vol.57 (5), p.204

1996

Volltextzugriff (PDF)

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Journal of clinical pharmacology, 2002-10, Vol.42 (10), p.1116-1121

2002

Volltextzugriff (PDF)

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

Clinical pharmacology and therapeutics, 1990-04, Vol.47 (4), p.499-503

1990

Volltextzugriff (PDF)

Mechanism by which hydralazine increases propranolol bioavailability

Clinical pharmacology and therapeutics, 1984-04, Vol.35 (4), p.447-453

1984

Volltextzugriff (PDF)

Age and ceftriaxone kinetics

Clinical pharmacology and therapeutics, 1984-01, Vol.35 (1), p.19-25

1984

Volltextzugriff (PDF)

Effects of nadolol and propranolol on plasma lidocaine clearance

Clinical pharmacology and therapeutics, 1984-11, Vol.36 (5), p.584-587

1984

Volltextzugriff (PDF)

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

Clinical pharmacology and therapeutics, 1984-07, Vol.36 (1), p.105-115

1984

Volltextzugriff (PDF)

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Journal of clinical pharmacology, 2002-10, Vol.42 (10), p.1116-1121

2002

Volltextzugriff (PDF)

SLEEP APNOEA IN A HYPERTENSIVE POPULATION

The Lancet (British edition), 1984-11, Vol.324 (8410), p.1005-1008

1984

Volltextzugriff (PDF)

Propranolol rebound—A retrospective study

The American journal of cardiology, 1978-04, Vol.41 (4), p.778-780

1978

Volltextzugriff (PDF)

Effect of dose and uremia on plasma and urine profiles of propranolol metabolites

Clinical pharmacology and therapeutics, 1980-06, Vol.27 (6), p.744-755

1980

Volltextzugriff (PDF)

the human immune response to KS1./4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies

Cancer research (Chicago, Ill.), 1991-05, Vol.51 (9), p.2286-2290

1991

Volltextzugriff (PDF)

1 – 25 von 36

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(20)

Publikationsform

Artikel
(36)

Sprache

Englisch
(36)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(33)
Science & Technology
(33)
Humans
(32)
Male
(25)
Adult
(24)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Pharmacology & Pharmacy
(21)
Pharmacology. Drug Treatments
(19)
Middle Aged
(17)
Female
(16)
Rosuvastatin Calcium
(14)
Aged
(12)
Drug Interactions
(12)
Area Under Curve
(10)
Fluorobenzenes - Pharmacokinetics
(10)
Cross-Over Studies
(9)
General And Cellular Metabolism. Vitamins
(9)
Double-Blind Method
(8)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Pharmacokinetics
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Pharmacodynamic effects and pharmacokinetics of a new HMG‐CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers

Population pharmacokinetics of rosuvastatin: implications of renal impairment, race, and dyslipidaemia

Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics

The effect of gemfibrozil on the pharmacokinetics of rosuvastatin

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease

An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers

Effect of itraconazole on the pharmacokinetics of rosuvastatin

Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects

The effect of a combination antacid preparation containing aluminium hydroxide and magnesium hydroxide on rosuvastatin pharmacokinetics

Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia

The effect of rosuvastatin on oestrogen & progestin pharmacokinetics in healthy women taking an oral contraceptive

No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy Volunteers

Pharmacokinetic interactions and side effects resulting from concomitant administration of lithium and divalproex sodium

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

Relationship between steady-state plasma nizatidine concentrations and inhibition of basal and stimulated gastric acid secretion

Mechanism by which hydralazine increases propranolol bioavailability

Age and ceftriaxone kinetics

Effects of nadolol and propranolol on plasma lidocaine clearance

Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon

No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG-CoA Reductase Inhibitor

SLEEP APNOEA IN A HYPERTENSIVE POPULATION

Propranolol rebound—A retrospective study

Effect of dose and uremia on plasma and urine profiles of propranolol metabolites

the human immune response to KS1./4-desacetylvinblastine (LY256787) and KS1/4-desacetylvinblastine hydrazide (LY203728) in single and multiple dose clinical studies

Suchergebnisse filtern